Connect with us
Advertise With Us


GSK Nigeria To Restructure Supply Chain Operating Model



The board of GlaxoSmithKline Consumer Nigeria Plc (GSK) said it has approved a change in the company supply chain model effective third quarter (Q3), 2021.

The board in a release said the decision is the outcome of an extensive review of its product supply operation, stressing that it the has approved a restructuring of GSK’s current operating model to serve the Nigerian patients and consumers better.

According to the statement the restructuring, which would be effective in Q3, 2021, involves working with local contract manufacturers for the supply of GSK’s products, where possible. Pointing out that this would support the building of local expertise, transfer of technical knowledge and improve local production capacities in the country.

The board expressed confidence that the proposed changes will allow the company to build a more sustainable commercial business, enabling it to continue with its ongoing efforts in supporting access to GSK’s consumer health products, medicines and vaccines.

The release explained that upon the successful transition of locally manufactured products to third-party contract manufacturing, the current GSK production operations in Agbara would be closed by Q3 2021.

“The identification of a suitable third party local manufacturer would be the subject of another announcement. Until then, it would be business as usual at the Agbara factory as GSK continues to ensure supply continuity for all its locally manufactured brands.”

The board assured It that these proposed changes would not impact GSK’s broader commitments to global health in Nigeria and across Africa. It also affirmed GlaxoSmithKline Consumer Nigeria Plc willingness to remain listed on the Nigerian Stock Exchange (NSE).



%d bloggers like this: